WO2021231648A3 - Cancer therapeutics comprising chemokine or its analog - Google Patents

Cancer therapeutics comprising chemokine or its analog Download PDF

Info

Publication number
WO2021231648A3
WO2021231648A3 PCT/US2021/032088 US2021032088W WO2021231648A3 WO 2021231648 A3 WO2021231648 A3 WO 2021231648A3 US 2021032088 W US2021032088 W US 2021032088W WO 2021231648 A3 WO2021231648 A3 WO 2021231648A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemokine
τgfβ
analog
antibody
cancer therapeutics
Prior art date
Application number
PCT/US2021/032088
Other languages
French (fr)
Other versions
WO2021231648A2 (en
Inventor
Erica Lyn STONE
Yoong Wearn LIM
Garry COLES
Adam Shultz ADLER
David Scott Johnson
Matthew SPINDLER
Original Assignee
Gigagen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gigagen, Inc. filed Critical Gigagen, Inc.
Publication of WO2021231648A2 publication Critical patent/WO2021231648A2/en
Publication of WO2021231648A3 publication Critical patent/WO2021231648A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure provides a method of treating cancer using a chemokine, e.g., a CCL5 mimetic. The chemokine can be used individually or in combination with other therapeutics, such as anti-PD-1 antibodies, anti-PD-Ll antibodies, and/or a ΤGFβ inhibitor (e.g., anti- ΤGFβ antibody). The present disclosure also provides a method of treating cancer using a a combination therapy with systemic administration of an anti-PD-Ll antibody and intratumoral administration of a ΤGFβ inhibitor (e.g., anti-ΤGFβ antibody).
PCT/US2021/032088 2020-05-12 2021-05-12 Cancer therapeutics comprising chemokine or its analog WO2021231648A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023790P 2020-05-12 2020-05-12
US63/023,790 2020-05-12

Publications (2)

Publication Number Publication Date
WO2021231648A2 WO2021231648A2 (en) 2021-11-18
WO2021231648A3 true WO2021231648A3 (en) 2021-12-23

Family

ID=78525228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/032088 WO2021231648A2 (en) 2020-05-12 2021-05-12 Cancer therapeutics comprising chemokine or its analog

Country Status (1)

Country Link
WO (1) WO2021231648A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114438029A (en) * 2022-01-21 2022-05-06 中山大学附属第一医院 Method for sorting intratesticular macrophages
WO2023172948A1 (en) * 2022-03-08 2023-09-14 Ohio State Innovation Foundation Ccl5 mrna nanoparticle and methods of use thereof
CN115590947A (en) * 2022-05-27 2023-01-13 苏州大学（Cn） Combined immunization drug, temperature-sensitive gel composition, chemokine particle and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070066523A1 (en) * 2002-09-13 2007-03-22 Chemokine Therapeutics Corp. Chemokine analogs for the treatment of human diseases
US20110097334A1 (en) * 2007-10-02 2011-04-28 Universitat Zu Koln Novel Marker Genes for Regulatory T Cells from Human Blood
US20140017227A1 (en) * 2011-01-14 2014-01-16 Suk Peng Chew Gene signatures for use with hepatocellular carcinoma
WO2017058896A1 (en) * 2015-09-28 2017-04-06 Sanford Burnham Prebys Medical Discovery Institute Targets for treatment of hepatocellular carcinoma cancer and methods related thereto
WO2019229616A1 (en) * 2018-05-28 2019-12-05 Orion Biotechnology Switzerland Sàrl Ccr5 inhibitor for use in treating cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070066523A1 (en) * 2002-09-13 2007-03-22 Chemokine Therapeutics Corp. Chemokine analogs for the treatment of human diseases
US20110097334A1 (en) * 2007-10-02 2011-04-28 Universitat Zu Koln Novel Marker Genes for Regulatory T Cells from Human Blood
US20140017227A1 (en) * 2011-01-14 2014-01-16 Suk Peng Chew Gene signatures for use with hepatocellular carcinoma
WO2017058896A1 (en) * 2015-09-28 2017-04-06 Sanford Burnham Prebys Medical Discovery Institute Targets for treatment of hepatocellular carcinoma cancer and methods related thereto
WO2019229616A1 (en) * 2018-05-28 2019-12-05 Orion Biotechnology Switzerland Sàrl Ccr5 inhibitor for use in treating cancer

Also Published As

Publication number Publication date
WO2021231648A2 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
WO2021231648A3 (en) Cancer therapeutics comprising chemokine or its analog
MY186582A (en) Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers
EP3878862A3 (en) Anti-coronavirus antibodies and methods of use
WO2021163064A3 (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
WO2018187227A8 (en) Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
WO2005070126A3 (en) Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
MX2021006681A (en) Anti-claudin antibodies and uses thereof.
MX2022006078A (en) Combination therapies for treating cancer.
WO2018081531A3 (en) Methods for human t-cell activation
EP4285929A3 (en) Combination hbv therapy
WO2018048941A3 (en) Methods to increase the duration of action of therapeutic monoclonal antibody products
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
WO2019204332A3 (en) Pak4 inhibitors and methods of use
WO2023178289A3 (en) Camptothecin conjugates
MX2022001403A (en) Methods of administering anti-siglec-8 antibodies and corticosteroids.
WO2001061017A3 (en) Modified cytokines for use in cancer therapy
WO2004094373A3 (en) A method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2021062085A8 (en) Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression
WO2019173593A8 (en) Diffusion barriers for metallic superconducting wires
WO2023028451A8 (en) Anti-cd-25 antibody
EP4268900A3 (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
MX2023009971A (en) Pharmaceutical composition containing anti-tslp antibody.
MX2023004831A (en) Methods of reducing tau in human subjects.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21803600

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21803600

Country of ref document: EP

Kind code of ref document: A2